GLP-1 Cost & Insurance
The transformative potential of GLP-1 medications is undeniable, but cost remains a significant barrier for many patients. Understanding pricing, insurance coverage, and savings programs is essential for accessing these life-changing treatments.
Understanding List Prices
Monthly Costs (2024)
| Medication | Form | List Price | Annual Cost |
|---|---|---|---|
| Ozempic | Injection | ~$935 | ~$11,220 |
| Wegovy | Injection | ~$1,349 | ~$16,188 |
| Mounjaro | Injection | ~$1,069 | ~$12,828 |
| Zepbound | Injection | ~$1,059 | ~$12,708 |
| Rybelsus | Oral | ~$935 | ~$11,220 |
| Trulicity | Injection | ~$930 | ~$11,160 |
| Victoza | Injection | ~$1,100 | ~$13,200 |
| Saxenda | Injection | ~$1,349 | ~$16,188 |
Note: Prices vary by pharmacy and region. These are approximate US cash prices.
Insurance Coverage Landscape
Coverage for Diabetes (Type 2)
Medications with diabetes indications generally have better coverage:
- Ozempic: Covered by most commercial insurance, Medicare Part D
- Mounjaro: Increasingly covered, good commercial coverage
- Rybelsus: Covered by most plans for diabetes
- Trulicity: Well-established coverage
- Victoza: Established coverage, often preferred
Coverage for Weight Loss
Weight management coverage is more variable:
- Wegovy: ~50% of commercial plans cover; Medicare excluded
- Zepbound: ~40-50% of commercial plans; Medicare excluded
- Saxenda: Similar to Wegovy coverage rates
Medicare Coverage
Current Medicare rules exclude weight loss drugs:
- Statutory exclusion: Medicare Part D cannot cover weight loss medications
- Diabetes exception: Ozempic, Mounjaro covered for diabetes
- Proposed changes: Legislation introduced to change this
- Medicaid: Varies by state; some cover weight loss drugs
Employer-Sponsored Plans
Large employers increasingly adding coverage:
- Tech companies often lead coverage expansion
- Some plans require step therapy (try diet/exercise first)
- Prior authorization typically required
- Check with HR or benefits administrator
Manufacturer Savings Programs
Novo Nordisk Programs
Ozempic Savings Card
- Up to $150 off per month
- For commercially insured patients
- Pay as little as $25 with eligible insurance
- Available at Ozempic.com
Wegovy Savings Card
- Up to $225 off per month
- For commercially insured patients
- $0 copay for some eligible patients
- Uninsured program: $25/month (while supplies last)
Rybelsus Savings Card
- Up to $150 off per month
- $25 copay with eligible commercial insurance
Eli Lilly Programs
Mounjaro Savings Card
- Up to $150 off per month
- $25 copay for eligible commercially insured
- Check Mounjaro.com for current offers
Zepbound Savings Card
- Up to $563 off per month
- $25 copay for eligible commercially insured
- Uninsured: $550/month via Lilly Direct
Program Limitations
Important restrictions apply:
- Medicare/Medicaid excluded: Cannot use with government insurance
- Commercial insurance required: Most require insurance to qualify
- Annual maximums: Some cards have yearly limits
- Program changes: Terms can change; verify current status
Alternative Cost-Reduction Strategies
Pharmacy Shopping
Prices vary significantly:
- Compare local pharmacies
- Check warehouse clubs (Costco, Sam's Club)
- Online pharmacies (legitimate, verified)
- Pharmacy discount programs (GoodRx, SingleCare)
Patient Assistance Programs
For uninsured, low-income patients:
- Novo Nordisk Patient Assistance:
- Free medications for qualifying patients
- Income requirements (≤400% federal poverty level)
- No insurance coverage required
- Apply through NovoCare.com
- Lilly Cares Foundation:
- Free medications for qualifying patients
- Similar income requirements
- Apply through LillyCares.com
Compounded Semaglutide
Some patients turn to compounded versions:
- Significantly cheaper: $150-300/month
- Not FDA-approved: Quality concerns
- Legal gray area: Regulatory uncertainty
- Risk considerations: Dosing, sterility, effectiveness
Caution: FDA has warned about some compounded products. Discuss risks with healthcare provider.
Insurance Prior Authorization Tips
Getting Approval
Improve your chances of coverage:
- Document diagnosis: Clear diabetes or obesity diagnosis
- BMI calculation: For weight loss, document BMI ≥30 (or ≥27 with comorbidities)
- Treatment history: Show diet/exercise attempts
- Comorbidities: List related conditions (hypertension, sleep apnea, etc.)
- Step therapy: Some plans require trying older medications first
Appealing Denials
If initially denied:
- Request formal appeal
- Get provider support letter
- Highlight medical necessity
- Mention failed alternatives
- Consider external review
Employer and Health System Strategies
Advocating for Coverage
Employees can influence benefits:
- Contact HR/benefits team
- Share clinical evidence of cost-effectiveness
- Highlight ROI (reduced diabetes complications)
- Reference peer companies offering coverage
- Join employee resource groups
The Economic Case
These medications can reduce overall costs:
- Reduced diabetes complications
- Lower cardiovascular event rates
- Decreased need for other medications
- Improved productivity
- Reduced surgical interventions
Long-Term Cost Considerations
Lifetime Treatment Costs
These medications are intended for chronic use:
- 10-year cost: $100,000-160,000
- 20-year cost: $200,000-320,000
- Offset by reduced complications
- Generic semaglutide expected ~2032
Cost vs. Value
Consider the full picture:
- Improved quality of life
- Reduced medication burden
- Prevention of expensive complications
- Increased longevity
- Enhanced productivity
The Bottom Line
GLP-1 medication costs are substantial but increasingly manageable:
- With good insurance: $25-100/month
- With savings cards: $25-200/month
- Patient assistance: $0 for qualifying patients
- Without coverage: $550-1,400/month
For those with coverage, these medications are life-changing investments in health. For those without, advocacy for expanded access continues at employer, insurer, and legislative levels.